Health facility-based Active Management of the Third Stage of Labor: findings from a national survey in Tanzania by Mfinanga, Godfrey S et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Health Research Policy and Systems
Open Access Research
Health facility-based Active Management of the Third Stage of 
Labor: findings from a national survey in Tanzania
Godfrey S Mfinanga*1, Godfather D Kimaro1, Esther Ngadaya1, 
Sirili Massawe2, Rugola Mtandu1, Elizabeth H Shayo3, Amos Kahwa1, 
Ominde Achola4, Alice Mutungi5, Rod Knight6, Deborah Armbruster6, 
David Sintasath6, Andrew Kitua3 and Cynthia Stanton6
Address: 1NIMR Muhimbili Medical Research Centre (MMRC), Dar es Salaam, Tanzania, 2Muhimbili University of Health and Allied Sciences 
(MUHAS), Dar es Salaam, Tanzania, 3National Institute for Medical Research (NIMR-HQ), Dar es Salaam, Tanzania, 4East Central Southern Africa 
Health Community, Family, and Reproductive Health Programme, Arusha, Tanzania (ECSA), 5Regional Center for Quality of Health Care, 
(Reproductive and Neonatal Health) (RCQHC), Jinja, Uganda and 6The Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
Email: Godfrey S Mfinanga* - gsmfinanga@yahoo.com; Godfather D Kimaro - fatherdk2002@yahoo.com; 
Esther Ngadaya - engadaya@yahoo.com; Sirili Massawe - smassawe@muchs.ac.tz; Rugola Mtandu - rugorugo@yahoo.com; 
Elizabeth H Shayo - bshayo@yahoo.com; Amos Kahwa - akahwa@hotmail.com; Ominde Achola - oachola@crhcs.or.tz; 
Alice Mutungi - amutungi@rcqhc.org; Rod Knight - rodjknight@aol.com; Deborah Armbruster - darmbruster@path-dc.org; 
David Sintasath - dsintasa@jhsph.edu; Andrew Kitua - akitua@nimr.or.tz; Cynthia Stanton - cstanton@jhsph.edu
* Corresponding author    
Abstract
Background: Hemorrhage is the leading cause of obstetric mortality. Studies show that Active
Management of Third Stage of Labor (AMTSL) reduces Post Partum Hemorrhage (PPH). This study
describes the practice of AMTSL and barriers to its effective use in Tanzania.
Methods: A nationally-representative sample of 251 facility-based vaginal deliveries was observed
for the AMTSL practice. Standard Treatment Guidelines (STG), the Essential Drug List and medical
and midwifery school curricula were reviewed. Drug availability and storage conditions were
reviewed at the central pharmaceutical storage site and pharmacies in the selected facilities.
Interviews were conducted with hospital directors, pharmacists and 106 health care providers in
29 hospitals visited. Data were collected between November 10 and December 15, 2005.
Results: Correct practice of AMTSL according to the ICM/FIGO definition was observed in 7% of
251 deliveries. When the definition of AMTSL was relaxed to allow administration of the
uterotonic drug within three minutes of fetus delivery, the proportion of AMTSL use increased to
17%. The most significant factor contributing to the low rate of AMTSL use was provision of the
uterotonic drug after delivery of the placenta. The study also observed potentially-harmful
practices in approximately 1/3 of deliveries. Only 9% out of 106 health care providers made correct
statements regarding the all three components of AMTSL. The national formulary recommends
ergometrine (0.5 mg/IM) or oxytocin (5 IU/IM) on delivery of the anterior shoulder or immediately
after the baby is delivered. Most of facilities had satisfactory stores of drugs and supplies.
Uterotonic drugs were stored at room temperature in 28% of the facilities.
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Conclusion: The knowledge and practice of AMTSL is very low and STGs are not updated on
correct AMTSL practice. The drugs for AMTSL are available and stored at the right conditions in
nearly all facilities. All providers used ergometrine for AMTSL instead of oxytocin as recommended
by ICM/FIGO. The study also observed harmful practices during delivery. These findings indicate
that there is a need for updating the STGs, curricula and training of health providers on AMTSL and
monitoring its practice.
Background
Postpartum hemorrhage (PPH) is one of the world's lead-
ing cause of maternal mortality. PPH occurs in over 10%
of all births and is associated with case a fatality rate of
1%. Twenty five percent of all maternal deaths are caused
by severe hemorrhage. [1,2] Recent information indicates
that worldwide the percentage is even higher than previ-
ously thought, ranging from 30–39%. [3] Reports from
Tanzania show that maternal deaths due to hemorrhage
were 23% in year 1988. [4]
Active management of the third stage of labor (AMTSL) is
a feasible and inexpensive intervention that can help to
save millions of women's lives. The AMTSL involves three
main components: The use of a uterotonic agents within
one minute following the birth of the baby, delivery of the
placenta with Controlled Cord Traction (CCT) and mas-
sage of the uterus after delivery of the placenta [5]
This definition is also supported by the World Health
Organization. [1,6] This definition differs from the origi-
nal research protocol in the Bristo trials which includes
immediate cord clamping and do not include massage.
[7,8] The FIGO/ICM Joint Statement and the WHO report
on the Managing Complications in Pregnancy and Childbirth,
do not include immediate cord clamping. [9] Studies
shows that there is now considerable evidence that early
cord clumping does not benefit mothers or babies and
may even be harmful. [10,11]
Clinical trials in developed countries show that the use of
AMTSL, in contrast to physiologic management of the
third stage of labor, significantly reduces PPH. [12] A
Cochrane review of these trials concludes by recommend-
ing AMTSL for all women delivering in a hospital and
anticipating the vaginal birth of a single baby. [12]
Based on this body of evidence, ICM and FIGO issued a
joint statement in November 2003, stating that every
woman should be offered AMTSL "as a means of reducing
the incidence of PPH due to uterine atony." The inclusion
of AMTSL in the WHO evidence-based manual Managing
Complications in Pregnancy and Childbirth also attests to the
international acceptance of this practice as the standard of
care. Evidence regarding adoption of this practice, how-
ever, is limited. Evaluations of donor funded projects
incorporating AMTSL tend to be limited to reporting on
the numbers of providers trained and the percent achiev-
ing competence following training. Apart from anecdotal
information, a 2003 article by the Global Network for
Perinatal and Reproductive Health offers a limited
glimpse into the adoption of this practice [13]. Their
results, based on an evaluation of the15 university-based
referral obstetric centers in developed and developing
countries, show substantial variation between and within
hospitals. There is insufficient evidence for drawing con-
clusions about the effectiveness of this practice in its
altered states. These results do suggest, however, that pro-
portions of the service providers using AMTSL is quite low
and, where it is practiced, the definition varies within and
between countries.
Since 1987, the Safe Motherhood Initiative has stated that
maternal mortality is an issue of health infrastructure.
AMTSL is a highly measurable, evidence-based, and life-
saving aspect of the health infrastructure. Given that PPH
is a leading cause of maternal death in many countries
with high maternal mortality, there is an important and
urgent need for information from these countries on cur-
rent practices regarding AMTSL. The aim of the study was
to provide descriptive information necessary to assess
AMTSL practices and identify major barriers to its use. The
study was conducted in 15 out of 21 regions of the Tanza-
nia Mainland.
Methods
Sample design, size, and study areas
This descriptive study was conducted from November to
December, 2005 to provide information on the use of
AMTSL and major barriers to its use at national and facil-
ity levels. Five types of data were collected to address the
study objectives. The data collected include; observations
of deliveries, short interviews with key informants regard-
ing procurement of AMTSL drugs and the content of pre-
and in-service medical and midwifery education, docu-
ment review of both the STG and pre-service curricula and
teaching materials for midwives and physicians regarding
AMTSL, and verification of the availability and storage
conditions of AMTSL drugs. The reviewed documents
included: 1) Advanced Life Saving Skills, volume 2: mod-
ule 1–10; Trainees manual-Reproductive and Child
Health section, MoH, Tanzania; 2) Proposal for upgrading
the diploma in nursing to a University of Dar es Salaam
(UDSM), Muhimbili University College of Health SiencesHealth Research Policy and Systems 2009, 7:6 http://www.health-policy-systems.com/content/7/1/6
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(MUCHS), February 2003; 3) Focused antenatal care
including prevention and treatment of malaria and syph-
ilis during pregnancy. Reference manual for nurses and
midwives. Tanzania, MoH, May 2004; 4) UDSM,
MUCHS, Eight semester Curriculum for the BSc Nusing
program, September 2002 and 5) UDSM Faculty of Nurs-
ing – Proposal for Conversion program, targeted group
Advanced diploma in Midwifery Degree, January, 2003
A nationally representative sample of facility-based deliv-
eries was selected. The study team selected the sample
using a two-stage design. To begin, 15 of the 21 regions in
the Tanzania mainland were selected with equal probabil-
ity.
These regions included Mtwara, Lindi, Ruvuma, Mbeya,
Iringa, Morogoro, Dodoma, Coast, Tanga, Kilimanjaro,
Arusha, Manyara, Mwanza, Shinyanga, and Dar es
Salaam. Data collectors then met with the regional medi-
cal officer (RMO) and regional Maternal and Child Health
(MCH) coordinator and obtained a current list of all hos-
pitals with at least two deliveries per day. From this list,
researchers randomly selected two hospitals to provide a
total of 30 hospitals. However, it was not possible to col-
lect data from one hospital.
The distribution among the remaining 29 hospitals sur-
veyed was as follows: 10 regional hospitals (one was both
a regional and referral hospital), 15 district hospitals, and
4 faith-based (church-affiliated) hospitals. Once at a
selected hospital, a data collector observed all deliveries
over two days for a period of 16 hours per day (7 am to 11
pm). The target sample size was 180 deliveries.
Training for data collectors
Twelve data collectors were trained to participate in the
fieldwork for this study, all of whom were either research
scientists or Medical Doctors. The 3-day training consisted
of discussion and presentations about various survey
questionnaires, role-playing exercise, demonstrations of
AMTSL with anatomical models and a pretest at two dis-
trict hospitals, during which all data collectors had the
opportunity to observe at least 9 deliveries under the
supervision of a study coordinator.
Definition of Terms
AMTSL definition: The study used two definitions of AMTSL:
Definition A is the FIGO/ICM definition, which involves
administration of 10 IU of oxytocin within 1 minute follow-
ing the delivery of the fetus, CCT, and immediate uterine
massage following delivery of the placenta. In cases where
oxytocin is not available 0.5 mg of ergometrine IM is recom-
mended. Definition B follows the same criteria as Definition
A but relaxes the time requirement for oxytocin administra-
tion from 1 to 3 minutes. This is also referred as "adequate"
use of the uterotonic drug.
Controlled Cord Traction (CCT): Researchers defined
CCT as the application of gentle traction of the umbilical
cord, with upward, manual support of the uterus, as a
means of delivering the placenta.
Data management and analysis
Data were double entered and validated using Epi Info™
(Version 6). Following the data cleaning process, descrip-
tive analyses were carried out using STATA (Version 8.0)
(College Station, TX, USA). Various proportions for deliv-
ery characteristics, providers' knowledge on AMTSL, and
AMTSL use according to definitions given were calculated
To reduce bias in the results, researchers applied weights
during analysis for both observation of deliveries and pro-
vider interviews. Delivery weights corrected for the
number of observed deliveries not being in proportion to
the number of reported deliveries per year. If, during the
observation period, the number of deliveries per day in a
facility is less than the average number of deliveries per
day for the entire year, the weight will adjust the value to
match the number of deliveries per day for the entire year.
Conversely, if the number of deliveries during the obser-
vation period was greater than the average number of
deliveries per day for the entire year, the value was
adjusted downward while provider weights adjusted for
the number of providers interviewed in relation to all pro-
viders managing deliveries in the facility.
If the number of providers interviewed in a facility was
less than the number that managed deliveries, the weight
adjusts the value to match the number that managed
deliveries. If the number interviewed matches the number
that manage deliveries, the weight would initially be 1.0,
because no adjustment is required. In a few cases, the
value was adjusted downward because health practition-
ers not managing deliveries directly were included in the
sample.
The final weights in these cases could differ from 1.0,
because another adjustment was made to ensure the over-
all weighted and unweighted sample sizes match. The n
values in all tables represent the weighted values. The
results report the weighted sample size, although the over-
all weighted sample size was designed to match the over-
all unweighted sample size, as mentioned above.
Ethical Approval
The protocol for this study was reviewed and approved by
the National Ethical Committee in Tanzania and also by
the Committee for Human Research at the Johns Hopkins
Bloomberg School of Public Health in Baltimore, Mary-
land USA, which considered it exempt from human sub-
jects research. Parturient women were asked their consent
to be observed upon admission to the hospital, or when
that was not possible, in the labor and delivery ward. Like-Health Research Policy and Systems 2009, 7:6 http://www.health-policy-systems.com/content/7/1/6
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wise, providers were asked for their consent to participate
in the face to face interviews. No identifiers of any kind
were collected.
Results
Individual health facility questionnaire
Researchers completed a questionnaire for each health
facility (n = 29) in which deliveries were observed. Inter-
views conducted with facility staff documented the
number of deliveries, policy information, and availability
and storage conditions of uterotonic drugs in the phar-
macy.
Health care providers
Interviews with health care providers at the maternity
ward documented attitudes and perceptions regarding the
routine use of AMTSL in those facilities. The study team
interviewed a total of 106 providers over a 2 day period in
each facility. The providers interviewed included nurse
midwives (64.4%), nurse officers (11.3) and others
(24.3%). The others category includes Assistant Medical
Officers, Mother and Child Health AID, medical attend-
ants, nurse assistants, and student nurses. Many of the
interviewed providers were also observed during delivery.
With regard to the health care providers' AMTSL knowl-
edge, only 9% made correct statements regarding all three
components as in the definition of AMTSL. These
included uterotonic drug administered within 1 minute
following the delivery of the fetus, CCT and uterine mas-
sage. Of all responses, 36% and 46% of providers men-
tioned one and two components, respectively. In general,
91% of providers made no correct statements regarding
the definition of AMTSL.
Policy, logistics, and drug availability
National standard treatment guidelines
The Tanzania Standard Treatment Guidelines (STG) and
the 1997 Essential Drug List (EDL) list registered two
types of uterotonic drugs: oxytocin and ergometrine. The
list indicates that oxytocin (5 IU) should be administered
intravenously (IV) for induction and augmentation of
labor and intramuscularly (IM) for stimulation of uterus
after delivery of fetus. The dose of ergometrine recom-
mended by STG and EDL for prevention of PPH is 0.5 mg/
IM.
AMTSL is minimally mentioned in the revised (l997) STG,
and the practice undefined. Oxytocin, unlike ergometrine,
is limited to hospital use and when prescribed by a physi-
cian.
The pre-service curricula and teaching materials for medi-
cal doctors and nurse-midwife students as shown in refer-
ence material listed in methodology section, do not
specifically mention AMTSL. However, the curricula on
preventing PPH recommends resources that advocate the
use of oxytocin (5 IU/IM) or ergometrine (0.5 mg/IM)
after delivery of the baby's anterior shoulder, followed by
umbilical cord clamping immediately after delivery and
removing the placenta by controlled cord traction. Uter-
ine massage following delivery of placenta is also men-
tioned in the curricula for the treatment of PPH.
Availability of uterotonic drugs
Oxytocin and ergometrine ampoules of 5 IU/ML and 0.5
mg/ML respectively were available at the central pharma-
ceutical storage site. Misoprostol and Syntometrine® was
not in the hospitals and in the government central Medi-
cal Store Department (MSD).
Both drugs are stored at a temperature of 2°C to 8°C and
restricted from light at the national storage site, where the
drugs are also stored in mobile cold boxes during procure-
ment. Several factors determine the quantity of drugs to be
procured: the previous monthly consumption rate, pur-
chasing power, and storage and distribution capacity.
Both oxytocin and ergometrine are readily available at
health facilities in Tanzania. For example, 97 percent of
observed deliveries occurred in facilities with either oxy-
tocin, ergometrine, or both available in the labor and
delivery ward.
Storage conditions
In nearly three-quarters (72%) of the health facility phar-
macies assessed, the storage conditions for oxytocin was
between 8°C and 25°C (without freezing). For
ergometrine, the storage temperature in 69% of visited
facilities was between 2°C and 8°C. About one third
(28%) of health facilities stored oxytocin and ergometrine
at room temperature.
Facility supplies of uterotonic drugs
We found a generally acceptable amount of oxytocin and
ergometrine in the facility pharmacies, with most health
facilities having a one-month uterotonic drug supply.
Drug availability was found to be problematic in certain
zones. For example, the Southern Highland zone – with
averages 400 deliveries per month – had less than one
week's supply of oxytocin. Similarly, the Eastern zone
reported enough ergometrine supplies for less than one
month, while nearly 750 deliveries were expected in the
next month.
Use of AMTSL
A total of 251 facility-based vaginal, non-instrumental
deliveries were observed in this study. The characteristics
of these observed deliveries are shown in Table 1. Almost
90% of the observations were conducted in regional or
district hospitals; 6% were in a central referral hospital.Health Research Policy and Systems 2009, 7:6 http://www.health-policy-systems.com/content/7/1/6
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Deliveries were observed in seven geographic zones
located throughout the Tanzania mainland. The volume
of deliveries in selected facilities varied substantially,
ranging from low-volume facilities (managing <1,200
deliveries per year; 4%) to high-volume facilities (>
10,000 deliveries per year; 27 percent).
Physicians were not observed in this study because they
tend to manage instrumental or more complicated deliv-
eries, which were excluded from this study sample. Con-
sequently, 71% of the observed deliveries were managed
by midwives and 11% by nurses. The mean age of moth-
ers was 25.1 years (range: 14 to 46 years). A majority of
the mothers were in the 2 to 5 gravidity group (58%) (See
table 1).
Use of uterotonic drugs
In the sample of observed deliveries, almost all women
received an uterotonic drug (ergometrine or oxytocin) at
some point during their deliveries (97%). Eight percent of
women were induced, and among spontaneous deliveries,
10% were augmented. About two-thirds (64%) of the
women observed received ergometrine, a quarter oxytocin
and 3% received both. Combination drugs such as Syn-
tometrine® or prostaglandins such as Misoprostol were
not used at all. The percent of deliveries for which
ergometrine and oxytocin were used was 67 and 31%
respectively, with no restrictions on timing, mode of
administration or dose.
Table 2 summarizes the use of uterotonic drugs by facility
and characteristics of the mothers. Use of ergometrine or
oxytocin varied little across these characteristics. Women
delivering at facilities managing 7,000 or more deliveries
per year were more likely to receive oxytocin compared to
women delivering at lower volume facilities. Use of
ergometrine was slightly higher among older and high
parity women (84 and 78% respectively).
Among women receiving ergometrine, which in Tanzania
appears to be the drug of choice during delivery, 3% of
women received this drug during delivery of fetus, 42% of
women received this drug after delivery of the fetus, and
45% received it after delivery of the placenta. An addi-
Table 1: Distribution of deliveries by facility and characteristics of the mother
Delivery characteristic % n Delivery characteristic % N
Type of facility Qualification of provider
Central referral hospital 5.7 14.1 Clinical Officers 1.1 2.8
Regional hospital 38.9 96.7 Midwife 71.3 176.8
District hospital 51.0 126.7 Nurse 11.1 2.5
Health center 0.5 1.3 Other* 11.6 28.8
Other 3.9 9.8 Missing 5.1 12.7
Volume of deliveries per year Age of mother
<1,200 4.4 10.9 <20 years 17.4 43.3
1,200 – 2,999 14.2 35.4 20–34 years 75.3 187.2
3,000 – 5,499 18.8 46.8 35+ years 7.2 18.0
5,500 – 6,999 17.7 43.9 Gravidity
7,000 – 9,999 18.1 45.1 1 32.8 81.5
10,000+ 26.7 66.4 2–5 58.0 144.2
Zone > 5 9.2 22.8





Southern Highlands 14.1 35.1
Western 3.9 9.7
Total 100.0 248.6
*Assistant Medical Officers, Mother and Child Health AID, medical attendants, nurse assistants, and student nurses.Health Research Policy and Systems 2009, 7:6 http://www.health-policy-systems.com/content/7/1/6
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tional 10% of cases had ergometrine administered during
delivery of the placenta. Among women receiving oxy-
tocin, about 12% received before delivery of fetus one
third (35%) received it following delivery of the fetus, 6%
received it during delivery of the placenta, and nearly half
(47%) received it following delivery of the placenta.
Use of AMTSL
Overall, only 7% of deliveries met the criteria for correct
use of AMTSL when ergometrine is used. This percentage
increases to 17 when the restriction regarding timing of
the administration of ergometrine is relaxed to within
three minutes of the delivery of the fetus. The percentage
of AMTSL use by Definitions A and B vary similarly by
characteristics of the mother and facility. In general,
women under 20 and over 35 years of age are more likely
to have had AMTSL, as are low and high parity women
respectively. The largest differences in the use of AMTSL
are by geographical zone. In the Central zone, 23% and
40% of deliveries met the criteria for Definitions A and B,
respectively. In the Lake and Northern zones, however,
none of the deliveries met the criteria for Definition A but
6% and 13% of observed deliveries met the criteria for
Definition B.
Elements of AMTSL
Controlled Cord Traction (CCT), and uterine massage
Observers could not detect if this action was taken only
after detecting signs that the placenta was beginning to
separate from the uterine wall (as specified in the FIGO/
ICM recommendation). According to the study's defini-
tion, providers performed CCT in over two-thirds (69%)
of observed deliveries. Nearly 88% of all deliveries bene-
fited from immediate uterine massage following delivery
Table 2: Distribution of the use of uterotonic drugs during labor, delivery, and the immediate postpartum period
Oxytocin only (%) Ergometrine only (%) Both (%) Neither (%) Missing data Total (%) N
Total 25.8 63.8 3.0 2.1 5.2 100.0 248.6
Age of mother
<20 years 20.4 66.8 4.3 0.0 8.6 100.0 43.3
20–34 years 28.3 61.2 2.7 2.8 4.9 100.0 187.2
35+ years 12.6 84.5 2.9 0.0 0.0 100.0 18.0
Gravidity
1 24.0 66.5 6.7 0.0 2.8 100.0 81.5
2–5 27.5 60.0 1.4 3.7 7.4 100.0 144.2
> 5 21.6 78.4 0.0 0.0 0.0 100.0 22.8
Type of facility
Referral hospital 11.1 81.5 3.7 3.7 0.0 100.0 14.1
Regional hospital 23.5 65.3 2.0 0.0 9.2 100.0 96.7
District hospital 31.0 59.0 3.1 3.8 3.2 100.0 126.7
Health center 0.0 100.0 0.0 0.0 0.0 100.0 1.3
Other 6.3 81.5 12.1 0.0 0.0 100.0 9.8
Volume of deliveries per year
<1,200 5.7 83.5 10.8 0.0 0.0 100.0 10.9
1,200 – 2,999 4.1 88.2 5.7 0.0 2.0 100.0 35.4
3,000 – 5,499 13.1 81.2 2.5 0.0 3.3 100.0 46.8
5,500 – 6,999 13.2 71.4 1.2 1.2 13.0 100.0 43.9
7,000 – 9,999 52.1 38.9 4.1 0.0 4.9 100.0 45.1
10,000+ 40.1 47.4 1.1 7.2 4.2 100.0 66.4
In-service training in selected facility:
For midwives 19.1 73.6 2.6 0.5 4.3 100.0 96.3
For nurses 19.1 73.6 2.6 0.5 4.3 100.0 96.3
For doctors 10.5 78.8 6.2 1.3 3.3 100.0 39.8Health Research Policy and Systems 2009, 7:6 http://www.health-policy-systems.com/content/7/1/6
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of the placenta. The study did not document palpation of
the uterus at 15 minute intervals following delivery of the
placenta.
Cord clamping in within one minute of fetal delivery was
practiced in three quarters of facility-based deliveries in
Tanzania. Researchers observed cord clamping within two
to three minutes of delivery with a large majority of the
remaining deliveries
The restrictions included in the definition of adequate rel-
ative to overall use, cause a drop of 44 percentage points
among births with ergometrine (dropping from 67 to
23%). The use of ergometrine during or following delivery
of the placenta accounts for virtually all of this decrease.
None of the deliveries met the criteria for adequate use
when oxytocin is used. The decrease from 31% to 0 is due
to both the administration of oxytocin at times other than
following the delivery of the fetus, and to the other dose
than the one recommended by ICM/FIGO. In 83% of the
deliveries where oxytocin was used, 5 versus 10 IU of oxy-
tocin were administered. The correct use of uterotonic
drugs is the same definition as adequate use, with the fur-
ther restriction that the uterotonic drug must be adminis-
tered within one minute of the delivery of the fetus. With
the restriction of administered uterotonic drug within one
minute of the fetus delivery, further decreases AMTSL use
from 23% to 9% among deliveries received ergometrine.
The additional requirements of controlled cord traction
and uterine massage among the providers using
ergometrine, further reduce correct use of AMTSL from 9
to 7%.
Potentially harmful practices
This study identified four potentially harmful practices in
251 observed deliveries. These practices include the appli-
cation of fundal pressure while awaiting the placenta
(44%), uterine massage following delivery of the fetus
(34%), and application of cord traction without manual
support of the uterus (21%). All of these practices can
increase the risk of PPH or cause problems such as uterine
inversion.
Discussion
The findings of low correct use of AMTSL using
ergometrine and non using oxytocin, reflect weakness in
the country STG which includes only two components:
the drug used (ergometrine) and CCT. The guidelines fail
to mention uterine massage following delivery of the pla-
centa.
The correct use of AMTSL according to ICM/FIGO defini-
tion, does prevent PPH by 60% and it is established that
about 1/3 of the MMR is due to PPH. [1-4] However, the
low rate of correct use of AMTSL practice, use of
ergometrine and suboptimal dosages of oxytocin are
major barriers to effective PPH prevention in the country
and this could slow down achievement of the MDGs of
reducing the MMR by 75% by 2015. [14] The low use of
correct AMTSL which is reported in this study has also
been observed elsewhere in the developed and developing
countries. [13]
Two practices are primarily responsible for low compli-
ance with the official definition of AMTSL: using uterot-
onic drugs during or following delivery of the placenta
(versus immediately following the delivery of the fetus),
and using uterotonic drugs within three (versus one
minute) following delivery of the fetus. The wrong timing
of administering uterotonic drugs was observed in about
half of deliveries in which ergometrine or oxytocin was
either administered before delivery of the fetus or after
delivery of placenta. This is in contrast to the FIGO/ICM
definition, recommending use of a uterotonic within one
minute of the delivery of the fetus. [5,15]
In addition, the observed poor AMTSL knowledge among
the providers interviewed reflect weakness in training pro-
grams. The observed poor knowledge is in sharp contrast
to the 93% who claimed they received AMTSL training
either during pre-service education, or with in-service
training.
It is, therefore, important for the Ministry of Health and
Social Welfare (MOHSW) to facilitate a process of updat-
ing national STG guidelines to include using of the recom-
mended dose of oxytocin (10 IU) and all AMTSL
components including proper massage, and the appropri-
ate timing of administration of a uterotonic drug (follow-
ing the delivery of the fetus) as recommended for AMTSL
by ICM/FIGO. [5,15]
The concerned authorities for learning institutions should
facilitate the process of incorporating the correct use of
AMTSL according to ICM/FIGO definition into both pre-
service and in-service training materials, and provide
refresher courses for MOHSW staff managing deliveries in
the country.
This study finding of a number of potentially harmful
practices including applying fundal pressure while wait-
ing for delivery of the placenta, gentle traction on the cord
without external support of the uterus, and external mas-
sage of the uterus while waiting for delivery of the pla-
centa, raise another concern in PPH control and maternal
health. All of these practices increase the possibility of
PPH or other problems such as uterine inversion. Pre-serv-
ice and in-service training should specifically emphasize
the potential danger to women when these practices are
used.Health Research Policy and Systems 2009, 7:6 http://www.health-policy-systems.com/content/7/1/6
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The U.S Pharmacopeia has changed their guidance on
storage of oxytocin from 15°C to 25°C to a narrower
range of 2°C to 8°C in the last few years. A recent review
of this change questioned the stringency of this require-
ment. It should also be noted that research has identified
that oxytocin can remain at room temperature up to 30°C
for 3 months. [16] In this study most of facilities stored
oxytocin and ergometrine properly. However, about one
third of the facilities improperly stored ergometrine at
room temperature. Most of the health facilities were
found to have uterotonic drug supplies enough for the
next one month only. Since oxytocin can be stored at
room temperature for up to three months[16], the facili-
ties could have ordered oxytocin stock enough for the next
three months instead of one month. However, storage at
room temperature should not be encouraged since we can
not ensure that such storage will not exceed three months.
The routine use of AMTSL, as recommended, is likely to
increase the use of oxytocin in the country. The procure-
ment, distribution and storage policies should be
reviewed to ensure that sufficient oxytocin supplies are
available and properly stored in hospitals, health centers,
and clinics. The policies should also ensure that there is
increased use of oxytocin and decreased ergometrine use
to comply with WHO, FIGO, and ICM standards. In addi-
tion, oxytocin is effective in 2–3 minutes after injection,
has minimal side effects, could be used in all women and
is more stable in storage than ergometrine. [16-18]
It is important to monitor and evaluate the use of AMTSL
using the updated definition, since AMTSL shows to
reduce the incidence of PPH, shortening of the third stage
of labor and reducing the need for additional treatments.
[9,17,18] Therefore, we recommend that supervisors are
trained in AMTSL and include items on the supervision
checklists to ensure its use as an indicator of quality. Labor
and delivery logbooks should include space to note and
monitor AMTSL use. Either the practice of implementing
clinical audits on AMTSL should be established.
The study was designed to assure a nationally representa-
tive sample of vaginal facility-based births. However, the
sample was restricted to public facilities due to difficulties
to obtaining permission to observe deliveries in private
facilities and limited funds. However, the four faith based
hospitals were included because they also served as desig-
nated district hospitals. Even though, the private hospitals
offering obstetric services are few and most them are
located in major cities, the four faith based hospitals are
not enough to fully describe AMTSL practice in private
hospitals.
In addition, the study sample was restricted to deliveries
occurring at national referral, regional and district hospi-
tals so that we could be sure of observing at least one
delivery per day. It was also of interest to compare AMTSL
practice in both low and high level facilities. Furthermore,
the sample size is not adequate for regions, districts or
facility based comparative analysis and therefore the inter-
pretation of our finding is limited at national level.
Conclusion
Correct practice of AMTSL according to the ICM/FIGO
definition was observed in 7% using ergometrine and non
using oxytocin. All providers used ergometrine for AMTSL
instead of oxytocin as recommended by ICM/FIGO. The
study observed harmful practices which included the
application of fundal pressure while awaiting the placenta
(44%), uterine massage following delivery of the fetus
(34%), and application of cord traction without manual
support of the uterus (21%). Only 9% of providers
responded correctly as regarding all three components as
in the definition of AMTSL. The drugs for AMTSL were
available in nearly all health facilities and were stored at
the right conditions in over 70% of the facilities visited.
The content of the training curricula for midwives and
physicians does include AMTSL as recommended by
FIGO/ICM. The study also observed harmful practices
during delivery. These findings indicate that there is need
for updating the STGs, curricula and training of health
providers on AMTSL and monitoring its practice.
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